Literature DB >> 3966794

Isolation and characterization of human liver guanine deaminase.

N K Gupta, M D Glantz.   

Abstract

Guanine deaminase (EC 3.5.4.3, guanine aminohydrolase [GAH]) was purified 3248-fold from human liver to homogeneity with a specific activity of 21.5. A combination of ammonium sulfate fractionation, and DEAE-cellulose, hydroxylapatite, and affinity chromatography with guanine triphosphate ligand were used to purify the enzyme. The enzyme was a dimer protein of a molecular weight of 120,000 with each subunit of 59,000 as determined by gel filtration and sodium dodecyl sulfate-gel electrophoresis. Isoelectric focusing gave a pI of 4.76. It was found to be an acidic protein, as evidenced by the amino acid analysis, enriched with glutamate, aspartate, alanine and glycine. It showed a sharp pH optimum of 8.0. The apparent Km for guanine was determined to be 1.53 X 10(-5) M at pH 6.0 and 2 X 10(-4) M for 8-azaguanine as a substrate at pH 6.0. The enzyme was found to be sensitive to p-hydroxymercuribenzoate inhibition with a Ki of 1.53 X 10(-5) M and a Ki of 5 X 10(-5) M with 5-aminoimidazole-4-carboxamide as an inhibitor. The inhibition with iodoacetic acid showed only a 7% loss in the activity at 1 X 10(-4) M and a 24% loss at 1 X 10(-3) M after 30 min of incubation, whereas p-hydroxymercuribenzoate incubation for 30 min resulted in a 91% loss of activity at a concentration of 1 X 10(-4) M. Guanine was the substrate for all of the inhibition studies. The enzyme was observed to be stable up to 40 degrees C, with a loss of almost all activity at 65 degrees C with 30 min incubation. Two pKa values were obtained at 5.85 and 8.0. Analysis of the N-terminal amino acid proved to be valine while the C-terminal residue was identified as alanine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3966794     DOI: 10.1016/0003-9861(85)90626-5

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  A novel transition state analog inhibitor of guanase based on azepinomycin ring structure: Synthesis and biochemical assessment of enzyme inhibition.

Authors:  Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2010-11-27       Impact factor: 2.823

2.  Guanine deaminase functions as dihydropterin deaminase in the biosynthesis of aurodrosopterin, a minor red eye pigment of Drosophila.

Authors:  Jaekwang Kim; Sang Ick Park; Chiyoung Ahn; Heuijong Kim; Jeongbin Yim
Journal:  J Biol Chem       Date:  2009-06-30       Impact factor: 5.157

3.  Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.

Authors:  José R Fernández; Eric S Sweet; William J Welsh; Bonnie L Firestein
Journal:  Bioorg Med Chem       Date:  2010-07-27       Impact factor: 3.641

4.  Extracellular guanosine regulates extracellular adenosine levels.

Authors:  Edwin K Jackson; Dongmei Cheng; Travis C Jackson; Jonathan D Verrier; Delbert G Gillespie
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-12       Impact factor: 4.249

5.  Analogs of iso-azepinomycin as potential transition-state analog inhibitors of guanase: synthesis, biochemical screening, and structure-activity correlations of various selectively substituted imidazo[4,5-e][1,4]diazepines.

Authors:  Saritha Tantravedi; Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem       Date:  2013-07-11       Impact factor: 3.641

6.  Discovery of a bacterial 5-methylcytosine deaminase.

Authors:  Daniel S Hitchcock; Alexander A Fedorov; Elena V Fedorov; Steven C Almo; Frank M Raushel
Journal:  Biochemistry       Date:  2014-11-19       Impact factor: 3.162

7.  Guanine Deaminase in Human Epidermal Keratinocytes Contributes to Skin Pigmentation.

Authors:  Joon Min Jung; Tai Kyung Noh; Soo Youn Jo; Su Yeon Kim; Youngsup Song; Young-Hoon Kim; Sung Eun Chang
Journal:  Molecules       Date:  2020-06-05       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.